Single-Arm Phase 2 Study Assessing SRF 388 in combination with pembrolizumab in patients with Non-Small-Cell Lung Cancer who have progressed after 1-3 prior lines of therapy
Latest Information Update: 09 May 2023
At a glance
- Drugs Casdozokitug (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Surface Oncology
Most Recent Events
- 04 May 2023 According to a Surface oncology media release, clinical data update will be provided in second quarter.
- 09 Mar 2023 According to Surface oncology media release, data from this trial is expected in the first half of 2023.
- 20 Apr 2022 New trial record